The agreement covers the exclusive distribution of the AFIAS-10 Single Test Immuno-Assay System, including IGRA-Tuberculosis across 34 countries in Europe.
FLORENCE, ITALY, April 19ᵗʰ 2023, A.Menarini Diagnostics S.r.l. (Menarini) is pleased to announce an exclusive distribution agreement for the AFIAS-10 System and IGRA-TB Assay (among others), building on several years of fruitful collaboration with Boditech Med Inc. (Boditech) in Italy.
This agreement grants Menarini with immediate availability the exclusivity for the distribution - in 34 countries across Europe - of the integrated sample-to-answer system AFIAS-10, a fully automated diagnostic platform that can perform independently 10 different tests in parallel.
AFIAS-10 features an easy-to-use testing procedure directly from blood collection tubes with multi-testing performance that provides prompt results and allows the quick transmission of medical information. The all-in-one cartridge for the AFIAS platform is ready-to-use and contains all assay reagents. At present it is available for the measurement of over 50 parameters.
IGRA-TB is a cytokine release assay for quantitative determination of Interferon Gamma (IFN-γ) produced by human blood cells stimulated with Mycobacterium tuberculosis (MTB) antigens. In particular, the AFIAS IGRA-TB test is a simple, fast and cost-efficient fluorescent immuno-assay that can be used on the AFIAS-10 platform, an optimal latent tuberculosis testing solution for a large range of laboratories typology.
Tuberculosis is one of the leading causes of death globally1. According to WHO, an estimated 10.6 million people contracted tuberculosis worldwide and a total of 1.6 million people died from the disease in 20211. In Europe, an estimated 230,000 people fell ill with tuberculosis in 2021 and, for the first time in two decades, the incidence rate is estimated to have increased by 1.2% compared to 20202.
Fabio Piazzalunga, Global Head of A. Menarini Diagnostics S.r.l., stated: “This agreement represents a great opportunity for our Company to contribute to the required efficiency of IVD services by bringing a highly innovative system for the immuno-assay single test market onto the EU market, being Afias-10 a perfect fit for decentralized use with cost effective positioning. The platform portfolio of assays includes tests with high medical value such as Latent Tuberculosis Testing. AFIAS-10 distribution will benefit from leveraging our strong sales and marketing forces deployed in the countries covered by the agreement”.
For more information, please visit: https://www.menarinidiagnostics.gr/el-gr/%CE%B1%CF%81%CF%87%CE%B9%CE%BA%CE%AE/%CE%B5%CF%80%CE%B1%CE%B3%CE%B3%CE%B5%CE%BB%CE%BC%CE%B1%CF%84%CE%B9%CE%BA%CE%B1-%CE%B4%CE%B9%CE%B1%CE%B3%CE%BD%CF%89%CF%83%CF%84%CE%B9%CE%BA%CE%B1/%CE%B1%CE%BD%CE%BF%CF%83%CE%BF%CF%87%CE%B7%CE%BC%CE%B5%CE%AF%CE%B1/afias-10
1. Global Tuberculosis Report 2022. Geneva: World Health Organization; 2022.
2. European Centre for Disease Prevention and Control, WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2023 – 2021 data.
About Boditech Med:
Boditech Med Inc. has been developing products for in-vitro diagnostics and diagnostic reagents for the past 20 years. The company based in Korea has been leading the way in exploring new markets through the automation of on-site diagnosed immunodiagnostic devices and the development of new high-sensitive diagnostic.
About A.Menarini Diagnostics, the Human Touch of Technology:
For more than 45 years, the company has been dedicated to helping healthcare professionals make safe and sustainable diagnoses, improving the quality of life of people all over the world.
A.Menarini Diagnostics is part of the Menarini Pharmaceutical Group, founded in 1886. Today it is present in 140 countries throughout the world, with more than 17,000 employees and 2022 turnover of € 4.154 billion.
For further information, please visit: www.menarinidiagnostics.com and LinkedIn.
For media enquiries:
Menarini Group, firstname.lastname@example.org, +39 055 56801